目的 探讨缬沙坦(Valsartan,Val)和氨氯地平(Amlodipine,Aml)联合应用对≥65岁老年高血压患者的临床疗效。方法 选取我院2014-01至2015-01确诊的年龄≥65岁的原发性老年高血压患者165例,以随机数字表法随机分为A(缬沙坦组)、B(氨氯地平组)、C(联合治疗组)三组,分别给予Val、Aml、Val + Aml治疗1年。观察比较3组治疗前后24 h平均血压的变化及不良反应发生情况。结果 A、B、C三组患者经过治疗之后24 h的收缩压和舒张压均明显下降(P<0.05),而A组和B组单独用药之间相比较,降压效果并没有明显的差异(P＞0.05), C组治疗后血压下降程度明显大于A、B两组(P<0.05)。联合治疗组的总有效率明显高于其他两个单药治疗组,差异有统计学意义(P＜0.05)。三组间不良反应发生率的差异无统计学意义(P＞0.05)。结论 缬沙坦和氨氯地平的联合应用对≥65岁老年高血压患者具有更好的临床疗效,值得推广应用。
Abstract
Objective To study the clinical efficacy of valsartan(Val) combined with amlodipine(Aml) for elderly hypertensive patients above 65.Methods 165 patients above 65 with primary hypertension were treateded in our hospital between January 2014 and January 2015. They were randomly divided into group A (valsartan), B (amlodipine), C (combination therapy group) according to the random number table. Patients in each group were treated wtih Val, Aml and Val+Aml for 1 year. The 24-hour mean blood pressure and adverse reactions of the three groups were observed.Results Systolic and diastolic pressure of group A, B and C after 24 hours of treatment decreased significantly(P<0.05), while the antihypertensive effect was not significantly different between group A and group B (P＞0.05).Blood pressure decreased more significantly in group C than in group A and B(P<0.05). The total effective rate of group C was significantly higher than that of group A and B(P<0.05). The incidence of adverse events was not significantly different between the three groups(P>0.05).Conclusions Valsartan combined with amlodipine has better clinical efficacy for hypertensive patients above65 and is worthy of clinical application.
关键词
缬沙坦 /
氨氯地平 /
老年高血压 /
临床疗效
Key words
valsartan /
amlodipine /
elderly patients with hypertension /
clinical curative effect
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Sison J, Assaadkhalil S H, Najem R, et al. Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study[J]. Curr Med Res Opin, 2014, 30(10):1937-1945.
[2] Shin S, Song H, Oh S K, et al. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients [J]. Hypertens Res,2013, 36(11):1000-1005.
[3] Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial [J]. JAMA,2013, 310(9):918-929.
[4] Zhu D, Yang K, Sun N, et al. Amlodipine/valsartan 5/160mg versus valsartan 160mg in Chinese hypertensives [J]. Int J Cardiol,2013,167(5):2024-2030.
[5] Ogawa H, Kim-Mitsuyama S, Matsui K, et al. Angiotensin II Receptor Blocker-based Therapy in Japanese Elderly, High-risk, Hypertensive Patients[J]. Am J Med, 2012, 125(10):981-990.
[6] Chow C K, Teo K K, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries [J]. JAMA, 2013, 310(9):959-968.
[7] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. European Heart Journal,2013,34(28):3-16.
[8] Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study [J]. Hypertension, 2010, 56(2):196-202.
[9] Kidambi S, Kotchen T A. Treatment of Hypertension in Obese Patients[J]. American Journal of Cardiovascular Drugs, 2013, 9(397):1624-1626.
[10] Mallat S G, Itani H S, Tanios B Y. Current perspectives on combination therapy in the management of hypertension[J]. Integr Blood Press Control, 2013, 6:69-78.
[11] Hu D, Liu L, Li W. Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study[J]. Adv Ther,2014, 31(7):762-775.
[12] 贾德安,王志坚, 杨士伟,等. 缬沙坦/氨氯地平或氨氯地平单药治疗高危高血压患者[J]. 中华高血压杂志, 2013(6):569-572.
[13] 刘 星, 唐海沁, 张亚文,等. 缬沙坦氨氯地平片治疗高血压有效性和安全性的系统评价[J]. 中华疾病控制杂志, 2015, 19(1):82-85.
PDF(522 KB)
